Browse Negotiations Image Banner

Banner Text Velit velaliquam, ultricies eros dolore magna in in doming ullamco sint. Sint doming dignissim in quis pariatur consequat urna eu providerent. Sint dolore ea urna velit doming ea pulvinar.

General Callout

Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.

Accordion

Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.

Heading 1

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Heading 2

Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.

Related content

Dolor commodo suscipit adipiscing suscipit, elit dolore velit. Amet tempuribud velit pariatur ullamco exercitation esse dolore sint velaliquam adipiscing eu pulvinar doming sunt, dignissim velit voluptate ex suscipit sunt ex, duis dignissim nunc tempuribud laboris commodo velit ut. Velit in harmud quis voluptate esse nulla.

Shop Now!

Laboris quis consectetur sed eros velit tempuribud suscipit magna ea consequat laboris. Elit adipiscing quis sunt duis magna nulla velit amet elit ex providerent consectetur tempuribud amet ex commodo urna, magna adipiscing elit sed duis nisi pulvinar, doming pariatur velaliquam quis providerent fugiat ea aliquip sit ut nisi sunt pulvinar eu velit.

grey rec centre

Call to action

Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate

Primary Button Secondary Button

Search by drug, manufacturer, or indication

Displaying 1021 - 1030 of 1165

Iclusig (ponatinib)

Status:

Concluded with an LOI

Manufacturer:

Paladin Labs Inc.

Indication:

Chronic Myeloid Leukemia/Acute Lymphoblastic Leukemia

Last updated July 4, 2016

Victoza (liraglutide)

Status:

Concluded without agreement

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated June 17, 2016

Jinarc (tolvaptan)

Status:

Negotiations were not pursued

Manufacturer:

Otsuka Canada Pharmaceutical Inc.

Indication:

Autosomal dominant polycystic kidney disease (ADPKD)

Last updated June 10, 2016

Cosentyx (secukinumab)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Psoriasis, moderate to severe plaque

Last updated June 8, 2016

Zydelig (idelalisib)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Chronic lymphocytic leukemia

Last updated June 3, 2016

Tafinlar/Mekinist (dabrafenib/trametinib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Metastatic Melanoma

Last updated May 25, 2016

Lemtrada (alemtuzumab)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Multiple Sclerosis, Relapsing-Remitting

Last updated May 11, 2016

Xeljanz (tofacitinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Rheumatoid Arthritis

Last updated April 26, 2016

Simponi IV (golimumab)

Status:

Concluded without agreement

Manufacturer:

Janssen Inc.

Indication:

Rheumatoid Arthritis

Last updated April 19, 2016

Tobi Podhaler (tobramycin)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Pseuodomonas aeruginosa infections in cystic fibrosis

Last updated April 19, 2016